Studies

GastroPanel® has been analysed in an increasing number of clinical and screening studies. This page provides the list of selected key studies with GastroPanel® (1-7).

To date, more than 1,000,000 patients have been tested using GastroPanel®. Most of these studies show that biomarker assays offer a reliable method for distinguishing patients with a healthy stomach from those suffering from a gastric morbidity (1-5) based on the use of gastroscopic biopsy as the gold standard. The he high negative predictive value (NPV) of the GastroPanel® test is particularly impressive, leveling off at 91-100%, and making GastroPanel® a highly accurate test in identifying a healthy stomach. In a population-based screening of nearly one thousand patients, the NPV was 98% (4). In the study by Ijima et al., (2009), GastroPanel® classified patients (n=196) into those with a healthy or non-healthy (HP cut-off) stomach, with 94% accuracy, 95% sensitivity and 93% specificity (1).  Testing of patients with dyspeptic complaints is particularly useful in identifying those at risk for gastric disease (e.g.atrophic gastritis and gastric cancer) from those who need other examinations for their symptoms (most likely due to other causes).

1. Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P and Shimosegawa T. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol. 2009 February 21; 15(7): 853–859.
 
2. Germaná B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, Comparato G, Carloni C, Bertiato G, Battiestel M, Papa N, Aragona G, Cavestro GM, Iori V, Merli R, Bertolini S, Caruana P, Franzé A. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis. 2005 Jul;37(7):501-8.
 
3. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandström R, Ristikankare M, Jussila A, Sipponen P. Non-Endoscopic Diagnosis of Atrophic Gastritis with a Blood Test. Correlation between Gastric Histology and Serum Levels of Gastrin-17 and Pepsinogen I. A Multicentre Study. Eur J Gastroenterol Hepatol 2003; 15: 885-891.
 
4. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M & Agreus L.Serum Biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda Study.  Scand J Gastroenterol 2008; 43:1448-1455.
 
5. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: Application of plasma biomarkers. Scand J Gastroenterol 2007; 42:2-10.
 
6. Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M, Sipponen P. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4256 volunteers without specific complaints. Scand J Gastroenterol 2010; 45:1036-1041.

7. Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, Syrjänen K: Prevalence of H. pylori Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan. A Hospital-based Screening Study Using a Panel of Serum Biomarkers. Anticancer Res. 2013 Oct;33(10):4595-4602

Further reading on GastroPanel® and dyspepsia

For further information, please see more detailed biomarker descriptions.

Search form: 

Search form